Effects of oral continuous 17β-estradiol plus norethisterone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition

Aim. To evaluate the effects of oral continuous 17β-estradiol plus norethisterone acetate (E2/NETA) replacement therapy on abdominal subcutaneous fat, serum leptin level (SLL) and body composition in postmenopausal women. Materials and methods. A 6-month, prospective, randomized, double-blind and placebo-controlled study was conducted. Forty-three healthy naturally postmenopausal women aged 43–65 years were randomly assigned to receive E2/NETA (2 mg E2 plus 1 mg NETA, n = 22) or placebo (n = 21). Fasting SLL by enzyme-linked immunosorbent assay, subcutaneous abdominal fat thickness (STh) by ultrasound and the anthropometric indices of body weight (BW), body mass index (BMI), waist and hip circumference (WC, HC) and waist-to-hip ratio (WHR) were recorded at the beginning and the end of the study. Results. After 6 months of therapy, BW and SLL increased in the placebo group (p = 0.043 and 0.033, respectively). WC, HC and STh decreased significantly in the E2/NETA group (p = 0.002, 0.006 and 0.000, respectively) and they were also significantly lower in women receiving E2/NETA than in women taking placebo (p = 0.000, 0.034 and 0.000, respectively). At baseline, SLL and STh were positively correlated with all anthropometric indices except WHR. Conclusion. Oral continuous combined regimen of E2/NETA significantly reduced central fat accumulation as assessed by WC and STh, and attenuated the increase in SLL. The observed changes in SLL were highly and positively related to changes in STh. The oral continuous combined E2/NETA regimen appears to have protective effects on cardiovascular function and probably on metabolic diseases by its slimming effect upon WC in postmenopausal women.

[1]  L. Dennerstein,et al.  The menopausal transition: a 9-year prospective population-based study. The Melbourne Women's Midlife Health Project , 2004, Climacteric : the journal of the International Menopause Society.

[2]  R. Ross,et al.  Waist circumference and not body mass index explains obesity-related health risk. , 2004, The American journal of clinical nutrition.

[3]  K. Machens,et al.  Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma? , 2003, Human reproduction.

[4]  R. Porcher,et al.  Changes in body composition during post-menopausal hormone therapy: a 2 year prospective study. , 2003, Human reproduction.

[5]  F. Folli,et al.  Ultrasound Measurement of Visceral and Subcutaneous Fat in Morbidly Obese Patients Before and after Laparoscopic Adjustable Gastric Banding: Comparison with Computerized Tomography and with Anthropometric Measurements , 2002, Obesity surgery.

[6]  C. Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[7]  R. Ross,et al.  Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. , 2002, The American journal of clinical nutrition.

[8]  F. Wieser,et al.  Current concepts in aesthetic endocrinology , 2002, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[9]  A. Genazzani,et al.  Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. , 2001, Maturitas.

[10]  H. Koistinen,et al.  Comparison between 1 year oral and transdermal oestradiol and sequential norethisterone acetate on circulating concentrations of leptin in postmenopausal women. , 2001, Human reproduction.

[11]  R. Walker,et al.  The effects of sequential combined oral 17&bgr;-estradiol norethisterone acetate on insulin sensitivity and body composition in healthy postmenopausal women: a randomized single blind placebo-controlled study , 2001, Menopause.

[12]  G. Kollios,et al.  Treatment of normal women with oestradiol plus progesterone prevents the decrease of leptin concentrations induced by ovariectomy. , 2000, Human reproduction.

[13]  L. Melton,et al.  Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women. , 2000, Metabolism: clinical and experimental.

[14]  M. Petroni,et al.  Leptin plasma concentrations are dependent on body fat distribution in obese patients , 2000, International Journal of Obesity.

[15]  A. Isidori,et al.  Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. , 2000, The Journal of clinical endocrinology and metabolism.

[16]  P. Vestergaard,et al.  Hormone replacement therapy affects body composition and leptin differently in obese and non-obese postmenopausal women. , 1999, The Journal of endocrinology.

[17]  C. Hayward,et al.  Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study. , 1999, Diabetes care.

[18]  R. Norman,et al.  Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. , 1999, The Cochrane database of systematic reviews.

[19]  J. Halaas,et al.  Leptin and the regulation of body weight in mammals , 1998, Nature.

[20]  R. Considine,et al.  Are leptin levels dependent on body fat distribution in obese men and women? , 1998, Eating and weight disorders : EWD.

[21]  P. Eriksson,et al.  Leptin secretion from subcutaneous and visceral adipose tissue in women. , 1998, Diabetes.

[22]  G. Kollios,et al.  Leptin concentrations in the follicular phase of spontaneous cycles and cycles superovulated with follicle stimulating hormone. , 1998, Human reproduction.

[23]  M. Kimura,et al.  The Influence of Ovariectomy on ob Gene Expression in Rats , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[24]  T. Price,et al.  Identification of progesterone receptor in human subcutaneous adipose tissue. , 1998, The Journal of clinical endocrinology and metabolism.

[25]  N. Sato,et al.  Estrogen increases in vivo leptin production in rats and human subjects. , 1997, The Journal of endocrinology.

[26]  P. Trayhurn,et al.  Circulating leptin in women: a longitudinal study in the menstrual cycle and during pregnancy , 1997, Clinical endocrinology.

[27]  S. B. Pedersen,et al.  Identification of steroid receptors in human adipose tissue , 1996, European journal of clinical investigation.

[28]  W. Kohrt,et al.  Serum leptin levels are reduced in response to exercise training, but not hormone replacement therapy, in older women. , 1996, The Journal of clinical endocrinology and metabolism.

[29]  S. Phinney,et al.  Gender differences in plasma leptin concentrations , 1996, Nature Medicine.

[30]  R. Leibel,et al.  Effects of gender, body composition, and menopause on plasma concentrations of leptin. , 1996, The Journal of clinical endocrinology and metabolism.

[31]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[32]  A Tremblay,et al.  Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. , 1994, The American journal of cardiology.

[33]  J. Coope,et al.  Can we improve compliance with long-term HRT? , 1992, Maturitas.

[34]  M. Zamboni,et al.  Sonography detection of small intra-abdominal fat variations. , 1991, International journal of obesity.

[35]  K. Pennert,et al.  Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. , 1984, British medical journal.